Stock Analysis
Agilent Technologies, Inc. (A) Stock Analysis
Agilent Technologies, Inc. (A) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Agilent Technologies, Inc. (A) currently has an AIQ Score of 60/100, indicating a neutral setup. Sentiment is the strongest factor at 80/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
A at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $177.75 |
| AIQ Score | 60/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $42.35B |
| P/E Ratio (TTM) | 29.46 |
| Forward P/E | — |
| EPS (quarter ended 2026-07-31) | $1.28 |
| Revenue (quarter ended 2026-07-31) | $1.88B |
| Dividend Yield (TTM) | 0.68% |
| Beta | 1.23 |
| Volume | 2.14M |
| 52-week range | $108.35-$178.21 |
| RSI 14 | 69.35 |
| 50-Day SMA | $160.42 |
| 200-Day SMA | $135.02 |
| Analyst Price Target | $168.85 |
| Next Earnings | Nov 23, 2026 |
AAgilent Technologies, Inc.
Healthcare / Medical - Diagnostics & Research
Low Priority
Above Peers
Latest quote
- Momentum77
- Value37
- Quality67
- Risk resilience64
- Sentiment80
A Stock Analysis Summary
Agilent Technologies, Inc. (A) currently has an AIQ Score of 60/100, indicating a neutral setup. Sentiment is the strongest factor at 80/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, A has AIQ Score of 60/100 with Sentiment base of 80/100 and fading Value at 37/100. Wait for component alignment before adding exposure.
Sentiment (80/100) leads while Value (37/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.74% stock move · A classified in Medical - Diagnostics & Research.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is A Bullish or Bearish Right Now?
A currently has a neutral overall setup. Sentiment is the strongest factor at 80/100, while Value is weakest at 37/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 67/100.
- - Momentum is constructive at 77/100.
- - Risk Resilience is supportive at 64/100.
- - Price is +10.80% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (36 vs 6).
- - Value is the current constraint at 37/100.
- - Analyst target implies -5.01% downside from the latest quote.
Current Consensus
A's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 3 neutral, and 6 sell votes. A's 14-day RSI is 69.35, which places the stock in a constructive momentum range. A's beta is 1.23, indicating greater market sensitivity than the broad market.
What Changed in A?
The largest recent change in A is Momentum moving up by 15.0 points over the available 7-day comparison window. Sentiment remains the strongest visible factor.
What Would Change the A Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
A Decision Framework
Public evidence layers, setup checks, and risk context for Agilent Technologies, Inc..
Agilent Technologies, Inc. (A) Stock Analysis
Agilent Technologies, Inc. has an AIQ Score of 60/100 in a Neutral regime. Sentiment is strongest at 80/100. Beta is 1.21, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | A is in a Neutral AIQ regime with score 60/100. |
| Signal Conflict | The primary conflict is that sentiment leads at 80/100 while value lags at 37/100. |
| Factor Evidence | Momentum 77/100 · Value 37/100 · Quality 67/100 · Risk 64/100 · Sentiment 80/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Sentiment is the strongest factor at 80/100.
Momentum is 77/100 and RSI (14) is 69.3.
A is in a Neutral regime at 60/100.
Risk factor is 64/100 with beta 1.21 and annual volatility 32.48%.
Current conflict: sentiment leads at 80/100 while value lags at 37/100.
A Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
A Fundamentals
A valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
A Technical Analysis
A technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
A Stock Catalysts
Track A earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
A Dividend Analysis
A dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
A Financial Data
A revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
A Risk Analysis
A volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
A Stock News
A stock news, market tone, recent headlines, and catalyst context.
A vs Life Sciences / Tools / CRO Peers
Current peer cohort: A · CDNA · CERT · CLVT · DHR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| A Current stock | 60/100 | 37/100 | 77/100 | 64/100 | 0.71 | 32.48% | Current |
| CDNA CareDx | 59/100 | 27/100 | 68/100 | 39/100 | 2.4 | 73.07% | A vs CDNA |
| CERT Certara | 56/100 | 53/100 | 69/100 | 49/100 | -0.08 | 59.65% | A vs CERT |
| CLVT Clarivate | 54/100 | 75/100 | 53/100 | 31/100 | -0.64 | 76.42% | A vs CLVT |
| DHR Danaher | 57/100 | 37/100 | 80/100 | 59/100 | 0.4 | 30.82% | A vs DHR |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jul 31, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching A
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for A
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
A Stock FAQ
What is A stock price today?
Agilent Technologies, Inc.'s current stock price is $177.75. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is A bullish or bearish right now?
A's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is A's market cap?
A's market cap is $42.35B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is A's current P/E ratio?
A's current P/E ratio is 29.46 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is A's RSI?
A's 14-day RSI is 69.35 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is A above its 50-day and 200-day moving averages?
A is 10.80% from its 50-day SMA and 31.65% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is A's next earnings date?
A's next earnings date is currently listed as Nov 23, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does A pay a dividend?
A's dividend yield is 0.68% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.